Panchsheel Organics Ltd.
Snapshot View

95.25 -2.00 ▼-2.1%

23 July 2021, 04:00:00 P.M.
Volume: 2,002

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.panchsheel.com
Financial Indicators
Market Cap 47.77 Cr.
Earnings per share (EPS) 9.98 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 9.54 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 79.13 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.20 Calculated using Price: 95.25
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.50 Cr. 5,015,400 Shares
FaceValue 10
Company Profile

Panchsheel Organics, incorporated in the year 1989, is a part of the Pharmaceutical Division of the Turakhia Brothers Group. Turakhia Brothers was founded in 1975 in the Mumbai, India. The Turakhia Group, promoters of the company, are engaged in the import-export trade of pharmaceutical raw materials since the past 25 years.

Panchsheel exports bulk actives to over 60 countries mainly in Europe, South East Asia, Japan and Latin America. The company's inherent strength lies in identifying relevant bulk drugs and selling them at affordable prices across the world.

Skilled people, modern equipment and broad experience contribute to the strength of Panchsheel Organics. Skilled production teams assure flexibility, efficiency and consistent standard in drugs manufacturing.

The R & D division of Panchsheel backed with experienced, highly qualified  teams provide sophisticated innovative solutions. Skilled production teams assure flexibility, efficiency and consistent standard in chemical manufacturing.

The current practices at Panchsheel are adherence to high quality and safety standards as well as full compliance with GMP procedures. The gaseous emissions are properly controlled and waste water is treated properly so as to ensure compliance with local and international risk, minimizing damage to persons and environment.

Panchsheel has free capacity in its five production sites in all over India. This capacity is would be used by interested companies for development and custom synthesis on strictly confidential terms.

Some of the basic operations carried out by Panchsheel are:

  • Hydrolysis
  • Condensation
  • Oxidation
  • Hydrogenation
  • Friedel Crafts
  • Grignard
  • Esterification
  • Nitration

Product range of the company includes:

  • Bulk Drugs - Alendronate Sodium Trihydrate,  Isoxsuprine HCL, Alprazolam, Itraconazole Pellets 22%, Amitriptyline HCL BP/USP, Ketoconazole BP/USP, Amlodipine Besylate etc.
  • Bittering Agent
  • Novel Drug Delivery System
  • Phytochemicals & Herbal Products

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.06%
1 Week
-6.80%
1 Month
-2.46%
3 Month
+5.66%
6 Month
+10.24%
1 Year
+75.90%
2 Year
+72.87%
5 Year
+19.81%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 12.37 8.01 10.49 10.55 15.43 14.48 14.57 14.05 16.08
Return on Capital Employed (%) 15.05 11.05 15.09 14.28 18.51 19.66 18.21 17.77 20.31
Return on Assets (%) 6.50 4.11 5.22 5.55 8.66 8.43 8.55 8.76 10.79

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 16 16 18 19 21 23 27 30 35
Non Curr. Liab. 3 2 3 4 4 2 1 0 1
Curr. Liab. 11 14 15 11 12 14 19 15 17
Minority Int.
Equity & Liab. 30 32 35 33 37 39 47 45 53
Non Curr. Assets 8 8 8 7 9 10 10 9 11
Curr. Assets 22 24 27 26 28 29 37 36 42
Misc. Exp. not W/O
Total Assets 30 32 35 33 37 39 47 45 53

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 30 33 39 36 40 40 42 48 51
Other Income 0 0 0 0 0 0 0 0 0
Total Income 30 33 39 36 41 40 42 49 51
Total Expenditure -27 -30 -35 -31 -35 -33 -36 -41 -42
PBIDT 4 3 5 5 6 7 7 7 9
Interest -1 -1 -1 -1 -1 0 -1 0 0
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1
Taxation -1 -1 -1 -1 -1 -2 -2 -2 -2
Exceptional Items
PAT 2 1 2 2 3 3 4 4 5

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 1 3 1 3 5 3 2 5
Cash Fr. Inv. 0 -1 -1 -1 -2 -3 -1 -1 -3
Cash Fr. Finan. -2 0 -2 0 -1 -1 -2 -2 -1
Net Change -1 0 0 0 -1 0 0 0 1
Cash & Cash Eqvt 0 0 1 0 1 1 0 1 2

Shareholding Pattern View Details

9 Qtrs 2019-03 (%) 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%)
Promoter 68.22 68.22 68.22 68.22 68.22 68.22 68.22 68.22 68.22
Public 31.78 31.78 31.78 31.78 31.78 31.78 31.78 31.78 31.78
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 15 Jul 2021
Shareholding for the Period Ended June 30 2021
Panchsheel Organics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Fri, 09 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please note that we have received information from M/s. Purva Sharegistry (I) Private Limited our Registrar and Share Transfer Agent via email dated July 8 2021 (attached herewith) regarding loss of share certificates and request for issuance of duplicate share certificates as detailed below:

Sr. No. Folio No. Name of the Shareholder Certificate No. Distinctive No. No. of shares
From To From To
1. K00784 Kokila Shah Jatin Shah 0035268 0035268 3496201
3496300
100
0044828 0044828 4452201
4452300
100
0045334 0045336 4502801 4503100 300

This information is being submitted pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015.

This is for your information and records only.
Wed, 07 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Mahendra Turakhia
Designation :- Managing Director / Whole Time Director

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Close Crossing 50 EMA From Above Close Crossing 50 EMA From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%